Glutathione S-transferase polymorphisms and survival in African-American and White colorectal cancer patients

Cancer Epidemiology

Volumn 33, Issue 3-4, 2009, Pages 249-256

  Jones, Beth A ^a   Christensen, Alice R ^a   Wise Sr , John P ^b   Yu, Herbert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN MAINE   (United States)

Author keywords

African American; Colorectal cancer; GST polymorphisms; Race; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; LEVAMISOLE; METHOTREXATE; OXALIPLATIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN TISSUE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SURVIVAL TIME; WILD TYPE;

AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 70349741302     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.08.004     Document Type: Article

References (58)

1. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30 (1995) 445-600
2. Dalhoff K., Buus Jensen K., and Enghusen Poulsen H. Cancer and molecular biomarkers of phase 2. Methods Enzymol 400 (2005) 618-627
3. Hayes J.D., and Strange R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61 (2000) 154-166
4. Boyer T.D., and Kenney W.C. Preparation, characterization and properties of glutathione S-transferases. In: Zakim D., and Vessey D. (Eds). Biochemical pharmacology and toxicology (1985), John Wiley & Sons, New York, NY
5. Lo H.W., and Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 7 (2007) 367-374
6. Strange R.C., Spiteri M.A., Ramachandran S., and Fryer A.A. Glutathione-S-transferase family of enzymes. Mutat Res 482 (2001) 21-26
7. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 Pt 1 (1994) 271-276
8. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286
9. Wiencke J.K., Kelsey K.T., Lamela R.A., and Toscano Jr. W.A. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 50 (1990) 1585-1590
10. Reszka E., Wasowicz W., and Gromadzinska J. Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr 96 (2006) 609-619
11. Shiga H., Heath E.I., Rasmussen A.A., Trock B., Johnston P.G., Forastiere A.A., et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5 (1999) 4097-4104
12. Yang G., Shu X.O., Ruan Z.X., Cai Q.Y., Jin F., Gao Y.T., et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103 (2005) 52-58
13. Hohaus S., Di Ruscio A., Di Febo A., Massini G., D'Alo F., Guidi F., et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 11 (2005) 2175-2179
14. Ambrosone C.B., Sweeney C., Coles B.F., Thompson P.A., McClure G.Y., Korourian S., et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61 (2001) 7130-7135
15. Okcu M.F., Selvan M., Wang L.E., Stout L., Erana R., Airewele G., et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10 (2004) 2618-2625
16. Norppa H. Cytogenetic biomarkers and genetic polymorphisms. Toxicol Lett 149 (2004) 309-334
17. Jiao L., Bondy M.L., Hassan M.M., Chang D.Z., Abbruzzese J.L., Evans D.B., et al. Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer 109 (2007) 840-848
18. Lecomte T., Landi B., Beaune P., Laurent-Puig P., and Loriot M.A. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
19. Ali-Osman F., Akande O., Antoun G., Mao J.X., and Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272 (1997) 10004-10012
20. Cotton S.C., Sharp L., Little J., and Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 151 (2000) 7-32
21. Harris M.J., Coggan M., Langton L., Wilson S.R., and Board P.G. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 8 (1998) 27-31
22. Holley S.L., Rajagopal R., Hoban P.R., Deakin M., Fawole A.S., Elder J.B., et al. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 28 (2006) 231-236
23. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
24. Vallbohmer D., Iqbal S., Yang D.Y., Rhodes K.E., Zhang W., Gordon M., et al. Molecular determinants of irinotecan efficacy. Int J Cancer 119 (2006) 2435-2442
25. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54 (1994) 4313-4320
26. Sun X.F., Ahmadi A., Arbman G., Wallin A., Asklid D., and Zhang H. Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival. World J Gastroenterol 11 (2005) 6875-6879
27. Rajagopal R., Deakin M., Fawole A.S., Elder J.B., Elder J., Smith V., et al. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis 26 (2005) 2157-2163
28. Mulder T.P., Verspaget H.W., Sier C.F., Roelofs H.M., Ganesh S., Griffioen G., et al. Glutathione S-transferase pi in colorectal tumors is predictive for overall survival. Cancer Res 55 (1995) 2696-2702
29. Le Morvan V., Smith D., Laurand A., Brouste V., Bellott R., Soubeyran I., et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8 (2007) 1693-1703
30. Ruzzo A., Graziano F., Loupakis F., Rulli E., Canestrari E., Santini D., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
31. Kweekel D.M., Koopman M., Antonini N.F., Van der Straaten T., Nortier J.W., Gelderblom H., et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 99 (2008) 1316-1321
32. Kweekel D.M., Gelderblom H., Antonini N.F., Van der Straaten T., Nortier J.W., Punt C.J., et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 45 (2009) 572-578
33. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., and Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19 (1998) 275-280
34. Srivastava S.K., Singhal S.S., Hu X., Awasthi Y.C., Zimniak P., and Singh S.V. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 366 (1999) 89-94
35. Jones B.A., Kasl S.V., Curnen M.G., Owens P.H., and Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer?. Cancer 75 (1995) 2103-2113
36. Jones B.A., Kasi S.V., Curnen M.G., Owens P.H., and Dubrow R. Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146 (1997) 394-404
37. Jones B.A., Kasl S.V., Howe C.L., Lachman M., Dubrow R., Curnen M.M., et al. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101 (2004) 1293-1301
38. Jones B.A., Liu W.L., Araujo A.B., Kasl S.V., Silvera S.N., Soler-Vila H., et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 17 (2008) 2825-2834
39. Howard J., Hankey B.F., Greenberg R.S., Austin D.F., Correa P., Chen V.W., et al. A collaborative study of differences in the survival rates of black patients and White patients with cancer. Cancer 69 (1992) 2349-2360
40. Beahrs O., Henson D., Hutter R., et al. Manual for staging of cancer. American Joint Committee on Cancer (1988), J.B. Lippincott Company, Philadelphia
41. Moertel C.G. Chemotherapy for colorectal cancer. N Engl J Med 330 (1994) 1136-1142
42. Wolpin B.M., and Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 134 (2008) 1296-1310
43. Potosky A.L., Harlan L.C., Kaplan R.S., Johnson K.A., and Lynch C.F. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20 (2002) 1192-1202
44. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 79 (1989) 340-349
45. Coles B.F., and Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 17 (2003) 115-130
46. Peters W.H., Boon C.E., Roelofs H.M., Wobbes T., Nagengast F.M., and Kremers P.G. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 103 (1992) 448-455
47. Howie A.F., Forrester L.M., Glancey M.J., Schlager J.J., Powis G., Beckett G.J., et al. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 11 (1990) 451-458
48. Clapper M.L., Hoffman S.J., and Tew K.D. Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta 1096 (1991) 209-216
49. Moorghen M., Cairns J., Forrester L.M., Hayes J.D., Hall A., Cattan A.R., et al. Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis 12 (1991) 13-17
50. Dogru-Abbasoglu S., Mutlu-Turkoglu U., Turkoglu S., Erbil Y., Barbaros U., Uysal M., et al. Glutathione S-transferase-pi in malignant tissues and plasma of human colorectal and gastric cancers. J Cancer Res Clin Oncol 128 (2002) 91-95
51. Cui H., Shen J., Lu D., Zhang T., Zhang W., Sun D., et al. 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy. Cancer Chemother Pharmacol (2007)
52. Lewis A.D., Forrester L.M., Hayes J.D., Wareing C.J., Carmichael J., Harris A.L., et al. Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. Br J Cancer 60 (1989) 327-331
53. Funke S., Brenner H., and Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9 (2008) 1079-1099
54. Goto S., Kamada K., Soh Y., Ihara Y., and Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93 (2002) 1047-1056
55. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res 60 (2000) 4053-4057
56. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., et al. Regulation of JNK signaling by GSTp. EMBO J 18 (1999) 1321-1334
57. McIlwain C.C., Townsend D.M., and Tew K.D. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25 (2006) 1639-1648
58. Braun M.S., Richman S.D., Quirke P., Daly C., Adlard J.W., Elliott F., et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26 (2008) 2690-2698